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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a major health problem and a leading cause of chronic
liver disease in the United States and Western countries. In humans, genetic factors greatly influence individual
susceptibility to NAFLD; nonetheless, the effect of inter-individual differences in the normal liver epigenome with
regard to the susceptibility to NAFLD has not been determined.
Results: In the present study, we investigated the association between the DNA methylation status in the livers of
A/J and WSB/EiJ mice and the severity of NAFLD-associated liver injury. We demonstrate that A/J and WSB/EiJ mice,
which are characterized by significant differences in the severity of liver injury induced by a choline- and folate-
deficient (CFD) diet exhibit substantial differences in cytosine DNA methylation in their normal livers. Furthermore,
feeding A/J and WSB/EiJ mice a CFD diet for 12 weeks resulted in different trends and changes in hepatic cytosine
DNA methylation.
Conclusion: Our findings indicate a primary role of hepatic DNA methylation in the pathogenesis of NAFLD and
suggest that individual variations in DNA methylation across the genome may be a factor determining and
influencing the vulnerability to NAFLD.
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Background
Nonalcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease and a major health
problem in the United States and developed Western
countries [1, 2]. The pathogenesis of NAFLD is complex
and involves dysregulation of several interdependent mo-
lecular processes, including lipid metabolism, insulin re-
sistance, immune response, inflammation, oxidative stress,
and apoptosis [1]. NAFLD has two principal pathological
phenotypic states – uncomplicated non-alcoholic fatty
liver (NAFL) and non-alcoholic steatohepatitis (NASH), a
progressive form of the disease characterized by lipid ac-
cumulation, inflammation, hepatocellular damage, and
fibrosis in the liver [3, 4] that has a greater risk of develop-
ing life threatening liver-related complications, including
hepatocellular carcinoma [5]. Importantly, in a recent
study, McPherson et al. [6], using sequential paired liver
biopsy samples from patients with histologically-confirmed
NAFLD, demonstrated that 44 % of individuals diagnosed
with NAFL progressed to NASH [6]. In light of this, it is
critical to identify cohorts susceptible to NASH develop-
ment at early stages of the disease progression; however,
most of the current studies have focused on identifying
the underlying molecular mechanisms of the pathogenesis
and progression of NAFLD [7] and less attention has been
given (i) to clarifying the determinants for the predispos-
ition to the development of NASH in certain individuals,
and (ii) how to identify these individuals. This is critical
not only for identifying subpopulations sensitive to
NAFLD, but also for its treatment and prevention, since
there are no approved therapeutic drugs for the treatment
of NASH [4, 8]. This indicates that there is an urgent need
for a better understanding of the molecular mechanisms
and processes associated with NASH development and for
the discovery of determinants and biomarkers for
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enhancing the diagnosis and monitoring the progression
to NASH [8].
The development of NAFLD and its progression to
NASH, liver fibrosis, and cirrhosis has been associated
with disease-specific genomic alterations, mainly with
distinct cytosine DNA methylation and gene expression
patterns [9–13]. Specifically, Murphy et al. demonstrated
that differences in cytosine genomic DNA methylation
can distinquish patients with NASH [10], and Pirola et
al. reported that the level of cytosine mitochondrial
DNA methylation is associated with the histological se-
verity of NASH [11]. It is clear that the development
and progression of NAFLD by itself can induce epigen-
etic alterations; however, epigenetic changes in the liver
may also have an impact on disease development and
progression. For instance, the results of comprehensive
genome-wide association studies (GWAS) on patients
with biopsy-confirmed NAFLD identified PNPLA3 (pata-
tin-like phospholipase domain containing 3) as a modi-
fier of NAFLD outcome [14] and demonstrated that the
genetic and epigenetic variations in the PNPLA3 gene
influence risk and features of NAFLD [14–16]. Addition-
ally, the results of recent epigenome-wide association
studies (EWAS) demonstrated that natural differences in
DNA methylation caused by genetic variations are asso-
ciated with metabolic traits and may contribute to com-
plex disease etiology [17]; nonetheless, the influence of
hepatic genome-wide epigenomic differences on suscep-
tibility and severity to NAFLD has not been investigated.
Based on these considerations the goals of this study
were (i) to determine whether or not the epigenome
status in normal livers affects the severity of NAFLD-
associated liver injury induced by feeding a choline- and
folate-deficient (CFD) diet, and (ii) to investigate the role
of specific DNA methylation changes in the pathogen-
esis of NAFLD liver injury. To achieve these goals, we
investigated the status of hepatic cytosine DNA methyla-
tion and histone H3K4 trimethylation (H3K4me3) in A/J
and WSB/EiJ mice fed a CFD diet. This diet consistently
induces fat-related liver injury and is the most efficient
and reproducible approach for inducing severe NAFLD-
associated liver damage and fibrosis in mice that resem-
bles the histopathological features of human NAFLD
[18, 19]. More importantly, NAFLD induced by a CFD
diet is an ideal model for studying the subgroup of
NASH patients with histologically advanced NASH [19].
We demonstrate that A/J and WSB/EiJ mice, which ex-
hibit significant variations in the severity of liver injury
induced by a CFD diet [20], are characterized by sub-
stantial differences in cytosine DNA methylation in their
normal livers, and that each strain of mice can be distin-
guished by its unique normal DNA methylation profile.
More importantly, the severity of NAFLD-like liver in-
jury in A/J and WSB/EiJ mice induced by the CFD diet
was accompanied by different trends and changes in cyto-
sine DNA methylation in their livers. This suggests that
the status of hepatic DNA methylome may influence indi-
vidual susceptibility to NAFLD. Furthermore, our findings
indicate that the evaluation of DNA methylation may
be helpful in diagnosis and monitoring the severity of
NAFLD-associated liver injury.
Results
Status of cytosine DNA methylation and histone H3K4
trimethylation in the livers of control A/J and WSB/EiJ mice
The status of cytosine DNA and histone H3K4 trimethy-
lation, a well-established major histone transcription-
activating mark [21], in the normal livers of A/J mice, a
strain characterized by a mild NAFLD-like liver injury,
and WSB/EiJ mice, a strain that exhibits severe NASH-
like liver injury induced by choline and folate deficiency
[20], was evaluated by methylated DNA immunoprecipi-
tation (meDIP) and chromatin immunoprecipitation
(ChIP) assays in combination with Agilent Mouse 2 ×
105 K CpG Island Microarrays that cover 16,030 CpG
islands of the mouse genome. Unsupervised hierarchical
clustering of the CpG methylation and histone
H3K4me3 data showed that A/J and WSB/EiJ mouse
strains could be distinguished by their hepatic CpG is-
land methylation and histone H3K4 methylation profiles
(Fig. 1). A further detailed analysis of the microarray
CpG island methylation data revealed substantial differ-
ences in cytosine DNA methylation patterns in the livers
of control A/J and WSB/EiJ mice (Table 1). Specifically,
the proportion of hypermethylated CpG islands in gen-
omic DNA isolated from the livers of control A/J mice
and located in the promoter, gene body, downstream, di-
vergent promoter, and total gene regions was signifi-
cantly greater than in WSB/EiJ mice (Table 1). In
contrast, DNA isolated from the liver of control WSB/
EiJ mice possessed a higher proportion of unmethylated
CpG islands than A/J mice (Table 1). In contrast to hep-
atic CpG island methylation, the proportion of histone
H3K4 trimethylation did not differ between the two
strains in the downstream, divergent, and total gene re-
gions, although there was a significant increase in the
proportion of histone H3K4 trimethylation in the pro-
moter region of A/J mice and in the gene body region of
WSB/EiJ mice (Table 1).
Effect of the CFD diet on CpG island DNA methylation in
the livers of A/J and WSB/EiJ mice
To elucidate further the role of cytosine DNA methylation
and histone H3K4 trimethylation in the susceptibility to
NAFLD and the association between these epigenetic
marks and histopathological severity and features of
NAFLD-associated liver injury, the status of CpG island
methylation and histone H3K4me3 in the livers of A/J and
Tryndyak et al. BMC Genomics  (2016) 17:298 Page 2 of 12
WSB/EiJ mice fed a CFD diet was investigated. Figure 2
shows that feeding the CFD diet resulted in marked
strain-dependent changes in CpG island methylation.
Unsupervised hierarchical clustering of the CpG island
methylation data showed two important findings: first, A/J
and WSB/EiJ mice fed the CFD diet could be distin-
guished from mice on the control diet within each strain
(Fig. 2a and b); and second, A/J and WSB/EiJ mice fed the
CFD diet exhibited different trends and patterns in hepatic
cytosine DNA methylation that were associated with the
severity of NALD-like liver injury.
To identify differentially methylated CpG islands
between the control and CFD diet-fed groups within
each strain, a t-test with Benjamini-Hochberg correction,
p < 0.05 was applied. A total of 3194 and 4725 CpG
islands was found to be differentially methylated, re-
spectively, in the livers of A/J and WSB/EiJ mice fed the
CFD diet (Fig. 2c). Further analysis of these CpG island
methylation changes demonstrated that feeding the CFD
diet caused marked differences in cytosine DNA methy-
lation between the two strains. Specifically, feeding the
CFD diet resulted in a marked increase in the proportion
of hypomethylated CpG islands in the livers of A/J mice,
while in the livers of WSB/EiJ mice, there was a marked
increase in the proportion of hypermethylated CpG
islands (Fig. 2c). The number of hypomethylated genes
in A/J CFD diet-fed mice corresponded to a greater
number of up-regulated genes, whereas the number of
hypermethylated genes in WSB/EiJ mice was associated
with a greater number of down-regulated genes (GEO
accession number GSE62362) [22]. Furthermore, pairing
DNA methylation and transcriptomic analyses of differ-
entially methylated genes identified 21 hypomethylated
and up-regulated CpG island promoter containing genes,
whereas not a single hypermethylated gene that correlated
inversely with gene expression was found in A/J mice
(Fig. 2d). An opposite trend of changes was found in WSB/
EiJ mice, where 203 CpG island promoter containing genes
Fig. 1 DNA methylation and H3K4me3 in the normal livers of A/J and WSB/EiJ mice. a MeDIP microarray analysis of CpG island methylation in
the normal livers of A/J and WSB/EiJ mice. b ChIP-on-chip analysis of H3K4me3 in the normal livers of A/J and WSB/EiL mice. Heat map illustrating
significant differences in hepatic CpG island methylation between A/J and WSB/EiJ control mice. Unsupervised hierarchical clustering analysis was
performed using one-way ANOVA with p value cut-off at 0.05. The color bar identifies high-methylated or high H3K4me3-enriched (red) and
low-methylated or low H3K4me3-enriched (green) CpG islands
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were hypermethylated and correlated inversely with gene
expression and only 41 genes were hypomethylated and
up-regulated (Fig. 2d, Additional file 1: Table S1).
In contrast to DNA methylation changes in the livers
of A/J and WSB/EiJ mice fed the CFD diet, only 552 and
1366 CpG islands, respectively, were found to have dif-
ferential enrichment by histone H3K4me3 (Additional
file 2: Figure S1). Importantly, no major differences in
histone H3K4me3 were found between A/J and WSB/EiJ
mice fed the CFD diet, although the promoter region
was slightly enriched in WSB/EiJ mice compared to A/J
mice, while the opposite trend occurred in the gene
body region.
CpG methylation changes are associated with key NAFLD
pathological pathways
To evaluate further whether or not changes in CpG is-
land methylation are involved in the deregulation of key
physiological pathways associated with NAFLD develop-
ment and determine if differences in cytosine DNA
methylation can explain the difference in severity of
NAFLD-like liver injury in A/J and WSB/EiJ mice fed
the CFD diet, a pathway enrichment analysis of the dif-
ferentially methylated CpG island genes was performed.
Analysis of differentially methylated CpG islands in the
livers of WSB/EiJ mice fed the CFD diet demonstrated a
strong enrichment in genes associated with cell prolifer-
ation and organismal injury and abnormalities; and lipid
metabolism, molecular transport, and small-molecule
biochemistry networks involved in the NAFLD patho-
genesis (Table 2). In the livers of A/J mice, the top mo-
lecular pathways enriched by differentially methylated
genes were pathways associated with cell morphology,
tissue development, and carbohydrate metabolism; org-
anismal injury and abnormalities, and cell death and
survival; lipid metabolism, molecular transport, and small-
molecule biochemistry (Table 2). Although some of the
differentially methylated CpG island networks were com-
mon to both strains of mice (e.g., lipid metabolism, mo-
lecular transport, and small-molecule biochemistry), the
major difference between the two strains was the exten-
sive hypermethylation in WSB/EiJ mice and extensive hy-
pomethylation in A/J mice. Importantly, these changes in
cytosine DNA methylation corresponded with the gene
expression in CFD diet-fed A/J and WSB/EiJ mice. For
example, Fig. 3 shows that the majority of the genes in the
metabolic PPAR-regulated network were hypomethylated
in the livers of A/J mice fed the CFD diet (Fig. 3a) and
hypermethylated in the livers of WSB/EiJ mice (Fig. 3b).
Previously, we demonstrated that the metabolic PPAR-
regulated network, a major network affected by CFD diets
[22], was activated in A/J mice and down-regulated in
WSB/EiJ mice [22]. In order to confirm this observation,
we evaluated the status of gene-specific cytosine DNA
methylation and gene expression of Apoe, Foxa1, and
Foxa2, three of the most differentially-methylated genes
of the PPAR-regulated network. Figure 4 shows that
the extent of Apoe, Foxa1, and Foxa2 promoter methy-
lation was increased by 94, 66, and 85 %, respectively,
in the livers of WSB/EiJ mice fed the CFD diet (Fig. 4a),
but was not changed, except for a minor decrease in
methylation of the Foxa2 gene, in the livers of A/J
mice (Fig. 4a). Importantly, hypermethylation of Apoe,
Foxa1, and Foxa2 in the livers of WSB/EiJ mice was
accompanied by a reduced expression of these genes
(Fig. 4b).
Table 1 Number of differentially methylated and H3K4me3-enriched CpG islands (CGIs) in hepatic DNA of control A/J and WSB/EiJ mice
Location MeDIP ChIP-on-chip














Promoter A/J 1254 0.40 P < 0.001 A/J 2578 0.47 P < 0.001
WSB/EiJ 1254 0.10 WSB/EiJ 2578 0.41
Gene Body A/J 2371 0.52 P < 0.001 A/J 4828 0.52 P = 0.015
WSB/EiJ 2371 0.14 WSB/EiJ 4828 0.54
Downstream A/J 128 0.57 P < 0.001 A/J 201 0.70 P > 0.05
WSB/EiJ 128 0.11 WSB/EiJ 201 0.66
Divergent promoter A/J 147 0.37 P < 0.001 A/J 341 0.35 P > 0.05
WSB/EiJ 147 0.07 WSB/EiJ 341 0.30
Total A/J 3900 0.48 P < 0.001 A/J 7948 0.50 P > 0.05
WSB/EiJ 3900 0.12 WSB/EiJ 7948 0.49
aCGI fragments with a negative Z score and p < 0.05 were considered being significantly hypomethylated, and CGI fragments with a positive Z score and p < 0.05
were considered being significantly hypermethylated
bThe H3K4me3 enrichment was considered to be significant if the CGI fragments ratio IP/input DNA p value was < 0.05
cComparisons in the extent of hypermethylation and H3K4me3 enrichment between A/J and WSB/EiJ mice were conducted by one-tailed z-tests
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Effect of the CFD diet on DNA methyltransferases
To evaluate mechanisms that may be associated with
changes in CpG island methylation induced by the CFD
diet, the expression of the maintenance DNA methyl-
transferase 1 (Dnmt1) and de novo DNA methyltransfer-
ases Dnmt3a and Dnmt3b genes was examined. Figure 5
shows that the expression of Dnmt1 and, especially,
Dnmt3a genes and the level of DNMT1 and DNMT3A
proteins were significantly increased in the livers of WSB/
EiJ mice fed the CFD diet, whereas feeding the CFD diet
did not change the expression of Dnmt1 and Dnmt3a
genes and DNMT1 and DNMT3A protein levels in the
livers of A/J mice. In contrast, the levels of Dnmt3b
mRNA and DNMT3B protein in the livers of CFD diet
fed A/J and WSB/EiJ mice did not differ from those in the
control mice (data not shown).
Discussion
Accumulated evidence in the field of genomic research
has indicated clearly that inter-individual genetic varia-
tions in hepatic lipid metabolism, oxidative stress re-
sponse, and proinflamamatory and fibrogenic pathways
greatly influence individual susceptibility, severity, and
pathological features of NAFLD in humans [23–27]; how-
ever, these variants account for only a small fraction of the
disease. In contrast, epigenetically-associated differences
in chromatin structure and gene expression may contrib-
ute to the entire spectrum of NAFLD-associated pheno-
typic alterations. Previously, we demonstrated that feeding
mice a CFD diet induced NAFLD-like liver injury that was
accompanied by substantial hepatic DNA methylation
changes, the magnitude of which correlated with the se-
verity of liver injury [28]. Importantly, similar findings
Fig. 2 MeDIP microarray analysis of CpG island methylation changes in the livers of A/J and WSB/EiJ mice fed a choline- and folate-deficient diet.
Heat map illustrating significant differences in hepatic CpG island methylation between A/J (a) and WSB/EiJ (b) mice fed the CFD diet. Unsupervised
hierarchical clustering analysis was performed using one-way ANOVA, with p value cut-off at 0.05. The color bar identifies high-methylated (red) and
low-methylated (green) genes. c Table showing the number of differentially methylated CpG islands in hepatic DNA in A/J and WSB/EiJ mice fed a
control or CFD diet. Z-scores were calculated with Agilent Genomic Workbench Light. d Algorithm of analysis of inversely differentially methylated and
expressed genes in the livers of A/J and WSB/EiJ mice fed a CFD diet
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have been reported by Murphy et al. and Pirola et al., who
demonstrated that differences in cytosine methylation of
hepatic genomic and mitochondrial DNA were associated
with the severity of morphological changes in patients
with a biopsy-confirmed NAFLD [10, 11].
In this study, we investigated whether or not variations in
normal hepatic cytosine DNA methylation affected the sus-
ceptibility to NAFLD and were associated with the severity
of NAFLD-associated liver injury. Our results demonstrate
that A/J mice, characterized by a mild NAFLD-like liver in-
jury, and WSB/EiJ mice, characterized by a severe NASH-
like liver injury [21], exhibited substantial differences in
cytosine DNA methylation in their normal livers, and that
each strain of mice could be distinguished by its unique
DNA methylation profile. Specifically, A/J mice were char-
acterized by a greater extent of CpG island methylation
compared to NASH injury-prone WSB/EiJ mice. This sug-
gests that the status of the DNA methylome of normal liver
may determine individual susceptibility to NAFLD.
These findings are in good agreement with a recent
report by Orozco et al. [17], who profiled the DNA
methylation status of livers from 90 inbred mouse strains
and demonstrated that a natural variation in CpG methyla-
tion levels is associated with metabolic traits and may con-
tribute to complex disease etiology [17]. Importantly, our
results demonstrate that mice with a lower hepatic DNA
methylation phenotype are more prone to liver injury.
Another major finding of this study is that differences
in CpG island-specific methylation responses, either hy-
pomethylation or hypermethylation, to feeding the CFD
diet were associated with the magnitude of NAFLD-
associated injury. The responses depended on the initial
status of CpG island methylation in the normal livers.
For example, in A/J mice, a strain that exhibited a more
methylated phenotype in the normal livers and a mild
NAFLD-like liver injury, the CFD diet caused hypo-
methylative changes in CpG islands, whereas in WSB/EiJ
mice, which are characterized by a less methylated original
hepatic phenotype and severe NASH-like liver injury,
feeding the CFD diet caused profound hypermethylative
changes driven by up-regulation of DNMT1 and DNMT3A
and concurrent inhibition of gene expression. This was
further demonstrated by methylation/expression changes
of Apoe (apolipoprotein E), Foxa1 (forkhead box A1), and
Table 2 Top molecular networks of differentially methylated CpG-island-containing genes in the livers of A/J and WSB/EiJ mice fed
the CFD diet
Genes in green color – hypomethylated; red color – hypermethylated; and black color – no change in methylation
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Foxa2 (forkhead box A2), genes essential in controlling
fundamental metabolic pathways and homeostasis in the
liver, which were among the top (in terms of both
significance and fold change) differentially methylated/
expressed transcripts. These findings are in a good ag-
reement with the previous report [11] that showed a
Fig. 3 Molecular network interactions between differentially methylated genes in the livers of A/J (a) and WSB/EiJ (b) mice significantly different
between control and CFD diets. The Ingenuity Pathway Analysis database was used to determine and visualize molecular pathways enriched by
the significant differentially methylated CpG islands of genes. Hypermethylated genes are marked in red color and hypomethylated genes in
green color
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significant up-regulation of DNMT1 and marked hyper-
methylation and down-regulation of the mitochondrially
encoded NADH-dehydrogenase 6 (MT-ND6) gene in
NASH patients.
Several studies have demonstrated that down-regulation
of the FOXA subfamily members, FOXA1 and FOXA3,
play an important role in the pathogenesis and progression
of NAFLD in both humans and experimental animals
[29–31]. Similarly, a recent study by Schierwagen et al.
demonstrated that feeding a Western diet induced
metabolic syndrome and development of NASH in Apoe-
deficient mice [32]. Furthermore, Benet et al. showed that
treatment of human hepatocytes in vitro or rats in vivo
with steatotic drugs repressed Foxa1 expression [33].
Mechanistically, the reduction of Foxa1 expression has
been associated with several pathological phenotypic
features of NAFLD, including induction of triglyceride
synthesis and accumulation, inhibition of fatty acid β-
oxidation, and homocysteinemia [29–31]. These effects
were attributed mainly to down-regulation of a number of
FOXA1-controlled genes in the lipid and one-carbon me-
tabolism networks. Several mechanisms might account for
the inhibition of Foxa1 in NAFLD, including direct re-
pression of Foxa1 via deregulation of the protein kinase C
pathway [29] and down-regulation of CCAAT/enhancer
binding protein beta (C/EBPβ) [34] or an indirect
Fig. 4 Status of promoter cytosine DNA methylation and gene expression of Apoe, Foxa1, and Foxa2 in the livers of mice fed a control or
choline- and folate-deficient diet. a Gene-specific cytosine DNA methylation was determined by using MeDIP DNA coupled with real time PCR
with primers specific to promoter regions of Apoe, Foxa1, and Foxa2 genes in the livers of control and CFD diet-fed groups. The results are
presented as the percent change of promoter methylation of each gene in the livers of mice fed the CFD diet relative to that in control groups,
which were assigned a 100 %. b qRT-PCR analysis of Apoe, Foxa1, and Foxa2 gene expression in the livers of mice fed a control or CFD diet. The
results are presented as the average fold change in the expression of each gene in the livers of mice fed the CFD diet relative to that in control
groups, which were assigned a value 1. White bars – control mice, black bars – mice fed the CFD diet. * - Significantly different from the strain-
matched control mice (mean ± SD, n = 5, fold change > 2.0, p <0.05)
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mechanism via inhibition of the TGF-beta signaling path-
way by hepatocyte nuclear factor 6 (HNF-6) [35] or de-
regulation of miR-122/FOXA1/HNF4a feedback loop [36].
In the present study, we describe another mechanism of
Foxa1 inhibition in NAFLD development and progres-
sion that is mediated by gene-specific cytosine DNA
hypermethylation and may be attributed to a profound
over-expression of DNA methyltransferases in the livers
of NAFLD-prone WSB/EiJ mice.
Conclusions
In conclusion, the results of the present study demon-
strate a primary role of DNA methylation in the patho-
genesis of NAFLD and emphasize the importance of the
between-individual variation in DNA methylation across
the genome as a factor determining the NAFLD vulner-
ability. Furthermore, our study suggests that the evalu-
ation of the DNA methylation status may be critical for
the assessment of the disease susceptibility and its sever-
ity. Additionally, considering the potential reversibility of
epigenetic changes, our study suggests that modulation
of DNA methylation may modify the severity of NAFLD-
associated liver injury.
Methods
Animals and experimental design
Male A/J and WSB/EiJ mice (6 weeks of age) were ob-
tained from the Jackson Laboratory (Bar Harbor, ME,
USA). These strains were selected because they exhibited
significant differences in the extent of NAFLD-associated
liver injury induced by a methyl-donor-deficient diet [22].
The in-life portion of this study, diet description, mouse
treatment, tissue collection, and results of histopatho-
logical and clinical chemistry analyses are described in de-
tail in Tryndyak et al. [22]. All experimental procedures
were reviewed and approved by the National Center for
Toxicological Research Animal Care and Use Committee.
Methylated DNA immunoprecipitation microarray analysis
Genomic DNA was isolated from mouse liver tissues
using DNeasy Blood and Tissue kits (Qiagen, Valencia,
CA, USA). Methylated DNA immunoprecipitation (MeDIP)
was performed with Methyl Miner Methylated DNA En-
richment kits (Life Technologies, Grand Island, NY, USA)
according to the manufacturer’s instructions. Briefly, 5 μg
of genomic DNA was randomly sheared by sonication
to an average length of 0.2–1.0 kb and divided into
immunoprecipitated and input portions. DNA from
Fig. 5 Expression of DNA methyltransferase genes in the livers of mice fed a CFD diet. qRT-PCR analysis of Dnmt1 and Dnmt3a mRNA transcripts (a)
and Western blot analysis of DNMT1 and DNMT3A proteins (b). The results are presented as the average fold change in the expression of each gene in
the livers of mice fed the CFD diet relative to that in control groups, which were assigned a value 1. White bars – control mice, black bars – mice fed
the CFD diet. * - Significantly different from the strain-matched control mice (mean ± SD, n = 5, fold change >2.0, p < 0.05)
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the immunoprecipitated portions was incubated for
1 h at room temperature with MBD-Biotin protein
coupled to M280 Streptavidin Dynabeads. The cap-
tured methylated DNA was eluted as a single fraction
using a high-salt elution and precipitated with etha-
nol. The immunoprecipitated DNA and input DNA
pellets were then dissolved in 30 μL of water for
labeling. Immunoprecipitated DNA and input DNA
samples were labeled with cyanine 3-dUTP and cya-
nine 5-dUTP, respectively, using an Agilent Genomic DNA
Labeling Kit Plus (Agilent Technologies, Santa Clara, CA,
USA). The labeled DNA samples were purified using Ami-
con Ultra-0.5 30 kDa columns (Millipore, Billerica, MA,
USA) and eluted with 22 μL of 10 mM Tris, 1 mM EDTA
buffer, pH 8.0. The labeled immunoprecipitated DNA and
input DNA were co-hybridized to Agilent Mouse 2 ×
105 K CpG Island Microarrays, containing ~97,652 oligo-
nucleotide probes covering 16,030 CpG islands, according
to the manufacturer’s protocol. All DNA samples from
control and CFD diet-fed A/J and WSB/EiJ mice in the
MeDIP microarray experiment were processed simultan-
eously. Microarrays were scanned on an Agilent DNA
microarray scanner and the resulting images were ana-
lyzed with Agilent Feature Extraction Software (Version
10.7.3). The combined Z-score for each probe was calcu-
lated with Agilent Genomic Workbench Light (Version
6.0). The data files were loaded into the ArrayTrack data-
base [37] for further statistical analyses.
Histone H3K4me3 chromatin immunoprecipitation
microarray analysis
Formaldehyde crosslinking and chromatin immunopre-
cipitation (ChIP) assays were performed with primary
antibodies against histone H3K4me3 (EMD Millipore,
Billerica, MA, USA) using a Magna ChIP™ A chromatin
immunoprecipitation kit (EMD Millipore). Sheared by
sonication and purified, immunoprecipitated DNA and
input DNA were amplified by a GenomePlex® Complete
Whole Genome Amplification kit (Sigma-Aldrich, St.
Louis, MO, USA). Amplified immunoprecipitated DNA
and input DNA samples were labeled with cyanine 3-
dUTP and cyanine 5-dUTP, respectively, using an Agilent
Genomic DNA Labeling Kit Plus (Agilent Technologies,
Santa Clara, CA, USA). The labeled DNA samples
were purified using Amicon Ultra-0.5 30 kDa columns
(Millipore, Billerica, MA, USA) and eluted with 22 μL of
10 mM Tris, 1 mM EDTA buffer, pH 8.0. The labeled
immunoprecipitated DNA and input DNA were co-
hybridized to Agilent Mouse 2 × 105 K CpG Island
Microarrays according to the manufacturer’s protocol.
Microarrays were scanned on an Agilent DNA microarray
scanner and the resulting images were analyzed with Agi-
lent Feature Extraction Software (Version 10.7.3). The
data files were loaded into the ArrayTrack database [37]
for Lowess normalization, calculation of the ratio of
immunoprecipitated/input DNA, and further statistical
analyses.
Functional analysis of significant differentially methylated
and H3K4me3-enriched genes
Ingenuity Pathway Analysis (IPA) software (Qiagen,
Redwood City, CA, USA) was used to determine molecu-
lar pathways and networks that were enriched for sign-
ificant differentially methylated or H3K4me3-enriched
genes identified from t test analyses. Significance values
was calculated based on a right-tailed Fisher’s exact test
that determined whether a pathway was overrepresented
by calculating whether the genes in a given pathway were
enriched within the data set compared to all genes on the
array; a p < 0.05 was selected as the cutoff for significance
based on IPA threshold recommendations. Only those
pathways with a p value below the threshold of p < 0.05
and having >3 representative genes in the data set were
considered significant.
RNA extraction and quantitative reverse transcription-PCR
(qRT-PCR)
Total RNA was extracted from liver tissue using RNeasy
Mini kits (Qiagen) according to the manufacturer’s instruc-
tions. Total RNA (2 μg) was reverse transcribed using
random primers and High Capacity cDNA Reverse Tran-
scription kits (Life Technologies) according to the manu-
facturer’s protocol. The following gene expression assays
(Life Technologies) were used for quantitative reverse-
transcription polymerase chain reaction (qRT-PCR): Dnmt1
(Mm01151063_m1); Dnmt3a (Mm00432881_m1), and
Dnmt3b (Mm01240113_m1). Reactions were performed in
a 96-well assay format using a QuantStudio™ 7 Flex Real-
Time PCR System (Life Technologies). Each plate con-
tained one experimental gene and a housekeeping gene
[Gapdh (Mm99999915_g1)], and all samples were plated in
duplicate. The relative amount of each mRNA transcript
was determined using the 2−ΔΔCt method [38] and the
results are presented as fold change. Values of fold
change > 2.0 and p < 0.05 were considered significant.
Western blotting
The level of DNMT proteins was determined by Western
blot analysis using primary antibodies against DNMT1,
DNMT3A, and DNMT3B (Abcam, Cambridge, MA,
USA) as described in Tryndyak et al. [22]. Equal protein
loading was confirmed by immunostaining against GAPDH
(Abcam).
Statistical analyses
Results are presented as mean ± S.D. Changes in gene spe-
cific methylation and expression were assessed by t-tests.
Comparisons in the extent of hypermethylation and
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H3K4me3 enrichment were conducted by one-tailed
z-tests. P-values < 0.05 were considered significant.
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